Protein Sciences Corporation, a biotechnology company, engages in developing and manufacturing recombinant human and veterinary vaccines, therapeutics, and diagnostics utilizing its baculovirus expression vector system technology. Its products include influenza vaccines, recombinant neuraminidase, SARS vaccines, and novel adjuvants. The company also offers protein production services; cGMP manufacture of commercial material; complex proteins for research and diagnostic applications; baculovirus protein expression kits; insect cell produced recombinant proteins for use in laboratory animals or for in vitro testing; and SARS research antigens; and influenza research antigens. It serves academic scientists and non-profit research institutes, as well as genomics, biotechnology, pharmaceutical, and vaccine companies. The company distributes its products and services in Japan.